Shilpa Medicare Ltd.
Snapshot View

632.00 +5.30 ▲0.9%

30 July 2021, 04:00:00 P.M.
Volume: 16,538

Overview View Details

Sector Healthcare Compare with Sector peers
Industry Pharmaceuticals & Drugs Compare with Industry peers
Website http://www.vbshilpa.com
Financial Indicators
Market Cap 5,152.09 Cr.
Earnings per share (EPS) 18.13 Trailing Twelve Months Ending 2021-03
Price-Earning Ratio (PE) 34.86 Trailing Twelve Months Ending 2021-03
Industry PE 35.15 Trailing Twelve Months Ending 2021-03
Book Value / Share 181.37 Trailing Twelve Months Ending 2021-03
Price to Book Value 3.48 Calculated using Price: 631.95
Dividend Yield 0.17 Period Ending 2020-03
No. of Shares Subscribed 8.15 Cr. 81,526,898 Shares
FaceValue 1
Company Profile

Shilpa Medicare, established in 1987, has carved a niche for itself in the exceedingly competitive and quality-conscious sphere of pharmaceuticals manufacturing. It produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.  

The company has earned its spurs as a successful and reliable partner within the pharmaceutical industry. Buyers within the country and from across the borders count on its fast track integrated process development and finely honed expertise of its skilled and experienced personnel. The company is already exporting to USA, Canada, Australia, Japan and European countries viz., Germany, Switzerland, Netherlands, Belgium, Spain, Greece, Cyprus, Italy, United Kingdom etc., South American countries like Mexico, Brazil, Columbia etc, African countries like Kenya, Nigeria and West Indies etc, Asian countries like Singapore, Taiwan, China, Malaysia, Thailand and closer to home to Iran, Egypt, Pakistan and Bangladesh.  Shilpa Medicare is synergizing strength through tie-ups for manufacturing products and co-marketing rights, for it believes in working together and sharing success.

Being proactive in approach, the company continually seeks out enquiry’s for development of new products drawing from the extensive knowledge-base of its qualified and experienced people as well as sophisticated facilities.

Product range of the company includes:

Oncology AP's

  • Anastrozole 
  • Bicalutamide 
  • Carboplatin 
  • Gemcitabine HCI
  •  Irinotecan HCl Trihydrate
  • Oxaliplatin 
  • Temozolomide 
  • Cisplatin 
  • 5-Fluoro
  • Bortezomib 
  • Capecitabine 
  • Decarbazine 
  • Docetaxel 
  • Gefitinib 
  • Hydroxy urea 
  • Imatinib Mesylate 
  • Lenalidomide 
  • Letrozole
  • Methotrexate 
  • Thalidomide 
  • Topotecan HCl
  • Zoledronic acid 

General APIs

  • Ambroxol HCl 
  • Ticlopidine HCl 
  • Buflomedil HCl 
  • Nifedipine 
  • Lamivudine 
  • Sildenafil Citrate 
  • Terfenadine 
  • Acebrophylline 
  • Phenylephrine HCl 
  • Ursodeoxycholic acid 

PRODUCTS UNDER DEVELOPMENT (Oncology)

  •  Bendamustine Cladribine
  •  Decitabine Disodium Pamidronate
  •  Epirubicin Exemustane
  •  Fludarabine Phosphate  Idarubicine
  •  Paclitaxel  Pemetrexed
  •  Lomustine  Methotrexate
  •  Pamidronic acid  Tandutinib 

NUTRITIONAL SUPPLEMENTS 

  • Chromium picolinate  Chromium polynicotinate   

DRUG INTERMEDIATES

  • Trans-4-amino cyclohexanol
  • 2-Amino-3,5-dibromobenzaldehyde
  • 1,3,5-Trimethoxy Benzene 
  • 1,3,5-Tribromo Benzene
  • 7-ethyl camptothecin 
  • 7-ethyl-10-hydroxy camptothecin

Awards & Achievements:

  • Karnataka State Govt. 'Best Enterpreneur Award'.
  • Govt. of India 'Best Enterpreneur Award'.
  • ‘Star Export House’ Status from Ministry of Commerce and Industry, Govt. of India
  • 'cGMP' Certificates from W.H.O. for 20 API's
  • 'Best Export Award' from Visvesvaraya Industrial Trade Centre, Bangalore, Govt. of Karnataka,  INDIA
  • 'Outstanding Industrial Award' from Indian Junior Chamber.
  • 'Registration with 'Russian Health Authority' for Ambroxol HCl
  • 'Certificate of Suitability' received from EDQM for Ambroxol HCl (R0-CEP 2004-201-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Ticlopidine HCl (R0-CEP 2005-004-Rev 00)
  • 'Certificate of Suitability' received from EDQM for Carboplatin (R0-CEP 2006-212-Rev 00)
  • Patent application on Irinotecan HCl Trihydrate 'An improved process for the preparation of Irinotecan HCl Trihydrate' published as WO2006016203 on date 2006-02-16
  • Patent file for Gemcitabine HCl and Anastrozole manufacturing process.
  • Filed ASMF/EDMF of Gemcitabine HCl over 21 EU countries
  • Filed ASMF/EDMF of Irinotecan HCl Trihydrate HCl over 27 EU countries
  • Filed ASMF/EDMF of Oxaliplatin HCl over 11 EU countries
  • 'Best District Export Award' received from FKCCI, Bangalore on 16.06.2007
  • Korean FDA Approved for Gemcitabine HCl & Ambroxol HCl
  • COS received from EDQM for Buflomedil HCl (R0-CEP 2006-080-Rev.00)
  • COS received from EDQM for Oxaliplatin EP (R0-CEP 2006-201-Rev.00)
  • 'Best District Export Award' received from FKCCI, Bangalore on 20.06.2008.
  • COS received from EDQM for Gemcitabine HCl EP (R0-CEP 2006-222-Rev 00)
  • 2010 - Shilpa Medicare Limited was granted certificate of GMP Compliance of Manufacturer for Gemcitabine Hydrochloride
  • 2012 - Shilpa Medicare Ltd has been conferred First Prize of the National Energy Conservation Award-2012 in the Drugs & Pharmaceuticals Sector from Ministry of Power, New Delhi.
  • 2013
    • Shilpa Medicare Limited (SML) produced five key HIV medicines i.e. Tenofovir, Emtricitabine, Cobicistat, Elvitegravir and a combination of the four, known as the Quad'' for sale in over 100 countries, depending on the medicine.
    • Shilpa Medicare Ltd has announced the Companys State of art facility at Pharma Park Jadcherla (SEZ), near Mahaboobnagar (AP) for undertaking ''Contract Research & Forward Integration i.e. Own Formulation'' (Manufacturing of Oral & Injectible (Onco Products) has started functioning partially.
  • 2015
    • India Pharma Awards 2015 Shilpa Medicare Ltd bagged UBM's Excellence in R&D Award -EUGMP received from Government of Upper Bavaria, Germany for Gemcitabine, Irinotecan HCl, Oxaliplatin and Temozolomide -Shilpa Medicare Ltd bagged Pharmexcil’s Patent Award for securing the most number of product patents. -Shilpa Medicare has benchmarked its quality processes against the world’s best quality standards in various areas of operation.
  • 2016
    • The Company be shifted from Plot No.10, Shop No.80, Rajendra Gunj, Raichur Karnataka- 584102 to #12-6-214/A1, Hyderabad Road, Raichur, Karnataka-584135 with effect from May 03, 2016.
  • -Shilpa Medicare to merge Navya Biologicals with itself.

Delivery View Details

Delivered Qty
Traded Qty

Performance View Details

1 Day
+0.85%
1 Week
+0.26%
1 Month
+17.18%
3 Month
+47.97%
6 Month
+49.80%
1 Year
+25.04%
2 Year
+78.03%
5 Year
+8.20%
9 years 2012-03 2013-03 2014-03 2015-03 2016-03 2017-03 2018-03 2019-03 2020-03
Return on Equity (%) 16.63 15.93 20.98 15.40 17.92 13.60 10.62 10.30 12.26
Return on Capital Employed (%) 18.02 15.04 20.48 17.90 19.90 15.91 11.71 11.05 12.41
Return on Assets (%) 10.66 9.64 12.23 9.18 11.58 9.20 7.41 7.56 8.62

Balance Sheet View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Shh. Funds 276 320 396 547 639 987 1,085 1,198 1,329
Non Curr. Liab. 31 99 105 154 67 251 153 167 257
Curr. Liab. 121 124 167 189 222 237 266 253 408
Minority Int. 5 9 10 14 2 -3 -5 -8 -8
Equity & Liab. 433 551 678 905 931 1,472 1,499 1,610 1,986
Non Curr. Assets 245 339 444 577 577 742 827 1,065 1,365
Curr. Assets 188 212 234 328 354 730 672 545 621
Misc. Exp. not W/O 0 0 0 0
Total Assets 433 551 678 905 931 1,472 1,499 1,610 1,986

Profit Loss View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Net Sales 318 371 571 614 716 779 789 733 908
Other Income 8 5 9 7 11 29 33 16 22
Total Income 326 376 581 621 728 809 821 749 930
Total Expenditure -257 -302 -455 -487 -556 -618 -638 -579 -693
PBIDT 69 75 125 133 171 191 184 170 237
Interest -2 -2 -4 -4 -4 -3 -3 -4 -5
Depreciation -14 -15 -23 -21 -23 -31 -37 -42 -44
Taxation -12 -10 -20 -35 -36 -42 -34 -26 -33
Exceptional Items 1 0 -3 0 -2 -5 20
PAT 41 47 75 73 106 111 110 118 155

Cash Flow View Details

Particulars 9 years 2012-03 Rs. Cr. 2013-03 Rs. Cr. 2014-03 Rs. Cr. 2015-03 Rs. Cr. 2016-03 Rs. Cr. 2017-03 Rs. Cr. 2018-03 Rs. Cr. 2019-03 Rs. Cr. 2020-03 Rs. Cr.
Cash Fr. Operatn. 57 44 70 69 129 37 45 147 124
Cash Fr. Inv. -152 -95 -49 -195 -109 -262 -9 -196 -289
Cash Fr. Finan. 10 66 -28 136 -20 313 -61 10 176
Net Change -86 15 -7 10 0 88 -25 -39 10
Cash & Cash Eqvt 2 17 9 18 6 100 74 34 45

Shareholding Pattern View Details

9 Qtrs 2019-06 (%) 2019-09 (%) 2019-12 (%) 2020-03 (%) 2020-06 (%) 2020-09 (%) 2020-12 (%) 2021-03 (%) 2021-06 (%)
Promoter 53.80 53.80 53.80 53.80 53.80 53.25 53.25 53.25 53.25
Public 46.20 46.20 46.20 46.20 46.20 46.75 46.75 46.75 46.75
Depository Receipts 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Promoter Holding Pledge (%) 9.29 9.88 9.77 10.26 10.26 0.81 0.81 0.81 0.00

Announcements View Details

Thu, 29 Jul 2021
Intimation U/R 30 Of The SEBI(LODR) Regulations
Shilpa Medicare Limited is pleased to announce that on successful confirmation of Prequalification of API Praziquental by WHO-Geneva. Praziquantel is used to treat schistosoma (infection with a type of worm that lives in the bloodstream) and liver fluke (infection with a type of worm that lives in or near the liver). Praziquantel is in a class of medications called anthelmintics. It works by killing the worms
Wed, 28 Jul 2021
Announcement U/R 30 Of The SEBI(LODR) Regulations- Reg.
Shilpa Medicare Limited (SHILPAMED) today announces receipt of confirmation of WHO - GENEVA approval for API Tenofovir Disoproxil Fumarate a medication used to treat chronic hepatitis B and to prevent and treat HIV/AIDS under pre- qualification program.
Mon, 19 Jul 2021
Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Pursuant to Regulation 30 of SEBI LODR please find enclosed a copy of the Postal Ballot Notice together with the Explanatory Statement seeking approval of the Members as per the resolution set out in the Notice of the Postal Ballot.

Technical Scans View Details

Fri, 30 Jul 2021
Stock Outperforming Benchmark Index in both 1 Week and 3 Month Stock Outperforming Benchmark Index in both 1 Week and 3 Month
Stock Outperforming Sectoral Index in both 1 Week and 3 Month Stock Outperforming Sectoral Index in both 1 Week and 3 Month
Strongly Outperforming Benchmark Index Strongly Outperforming Benchmark Index
Strongly Outperforming Sectoral Index Strongly Outperforming Sectoral Index
Close Within 2 Year High Zone Close Within 2 Year High Zone

Related Stocks View Details

Stock Name Market Cap(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. 185,708.53 774.00 +10.1%
Divi's Laboratories Ltd. 129,702.64 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. 78,400.54 4,712.70 +0.9%
Cipla Ltd. 74,235.31 920.30 +4.3%
Cadila Healthcare Ltd. 59,986.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. 57,873.32 4,025.00 -0.3%
Aurobindo Pharma Ltd. 53,701.27 916.50 +0.9%
Stock Name Statement TTM Ending Price Earning Ratio(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 63.95 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 65.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 45.13 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 30.87 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 28.12 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 384.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 10.07 916.50 +0.9%
Stock Name Statement TTM Ending Price To Book Value(TTM) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2021-03 4.00 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2021-03 13.95 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-06 4.39 4,712.70 +0.9%
Cipla Ltd. Consolidated 2021-03 4.05 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 4.62 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2021-03 12.60 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2021-03 2.45 916.50 +0.9%
Stock Name Statement Year Ending Debt Equity Ratio LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 0.18 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 0.00 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 0.17 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 0.18 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 0.35 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 1.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 0.33 916.50 +0.9%
Stock Name Statement Year Ending Return On Equity(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 9.66 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 19.30 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 11.53 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 10.09 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 18.30 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 13.08 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.53 916.50 +0.9%
Stock Name Statement Year Ending Return On Capital Employed(%) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 10.07 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 25.36 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 15.24 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 12.53 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 13.65 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 17.13 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 18.80 916.50 +0.9%
Stock Name Statement Year Ending Net Sales(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 32,837.50 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 5,394.42 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 19,047.50 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 17,131.99 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 15,102.20 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 11,246.80 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 23,098.51 916.50 +0.9%
Stock Name Statement Year Ending Profit After Tax(Rs. Cr.) LTP Chg %
Sun Pharmaceutical Industries Ltd. Consolidated 2020-03 4,186.79 774.00 +10.1%
Divi's Laboratories Ltd. Consolidated 2020-03 1,376.54 4,885.80 +0.8%
Dr. Reddy's Laboratories Ltd. Consolidated 2021-03 1,903.60 4,712.70 +0.9%
Cipla Ltd. Consolidated 2020-03 1,546.98 920.30 +4.3%
Cadila Healthcare Ltd. Consolidated 2021-03 2,137.60 585.95 +2.5%
Apollo Hospitals Enterprise Ltd. Consolidated 2020-03 434.90 4,025.00 -0.3%
Aurobindo Pharma Ltd. Consolidated 2020-03 2,844.69 916.50 +0.9%